Skip to main content
NCBI home page
Gut logoLink to Gut
. 1984 Feb;25(2):125–128. doi: 10.1136/gut.25.2.125

Effects of chronic oral cimetidine on apparent liver blood flow and hepatic microsomal enzyme activity in man.

T K Daneshmend, M D Ene, G Parker, C J Roberts
PMCID: PMC1432271  PMID: 6693040

Abstract

Cimetidine 200 mg three times daily and 400 mg at night was given to 10 subjects for four weeks. Apparent liver blood flow was measured by indocyanine green clearance and microsomal enzyme activity by antipyrine clearance, before and after cimetidine. There was no reduction in indocyanine green clearance but antipyrine clearance, as expected, was significantly reduced by 15% at four weeks. Chronic cimetidine treatment does not reduce apparent liver blood flow and is therefore unlikely to be of use in the treatment of portal hypertension. The cimetidine associated hepatic enzyme inhibition appears to persist with prolonged treatment. Therefore patients on chronic cimetidine remain vulnerable to certain drug interactions.

Full text

PDF
125

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Algozzine G. J., Stewart R. B., Springer P. K. Decreased clearance of phenytoin with cimetidine. Ann Intern Med. 1981 Aug;95(2):244–245. doi: 10.7326/0003-4819-95-2-244_2. [DOI] [PubMed] [Google Scholar]
  2. Andreasen P. B., Vesell E. S. Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration. Clin Pharmacol Ther. 1974 Dec;16(6):1059–1065. doi: 10.1002/cpt19741661059. [DOI] [PubMed] [Google Scholar]
  3. Bauman J. H., Kimelblatt B. J. Cimetidine as an inhibitor of drug metabolism: therapeutic implications and review of the literature. Drug Intell Clin Pharm. 1982 May;16(5):380–386. doi: 10.1177/106002808201600504. [DOI] [PubMed] [Google Scholar]
  4. Branch R. A., Shand D. G., Wilkinson G. R., Nies A. S. Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. J Clin Invest. 1974 Apr;53(4):1101–1107. doi: 10.1172/JCI107647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Burroughs A. K., Walt R., Dunk A., Jenkins W., Sherlock S., Mackie S., Dick R. Effect of cimetidine on portal hypertension in cirrhotic patients. Br Med J (Clin Res Ed) 1982 Apr 17;284(6323):1159–1160. doi: 10.1136/bmj.284.6323.1159-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. CAESAR J., SHALDON S., CHIANDUSSI L., GUEVARA L., SHERLOCK S. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci. 1961 Aug;21:43–57. [PubMed] [Google Scholar]
  7. Daneshmend T. K., Jackson L., Roberts C. J. Physiological and pharmacological variability in estimated hepatic blood flow in man. Br J Clin Pharmacol. 1981 May;11(5):491–496. doi: 10.1111/j.1365-2125.1981.tb01155.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Daneshmend T. K., Roberts C. J. Cimetidine and bioavailability of labetalol. Lancet. 1981 Mar 7;1(8219):565–565. doi: 10.1016/s0140-6736(81)92903-2. [DOI] [PubMed] [Google Scholar]
  9. Danhof M., Groot-van der Vis E., Breiner D. D. Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man. Pharmacology. 1979;18(4):210–223. doi: 10.1159/000137254. [DOI] [PubMed] [Google Scholar]
  10. Dutt M. K., Moody P., Northfield T. C. Effect of cimetidine on renal function in man. Br J Clin Pharmacol. 1981 Jul;12(1):47–50. doi: 10.1111/j.1365-2125.1981.tb01853.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. El-Gendi M. A., Nassar S. H. Effect of histamine and histamine antagonists on portal blood pressure in patients with hepatosplenic schistosomiasis. Br J Clin Pharmacol. 1980 Aug;10(2):157–161. doi: 10.1111/j.1365-2125.1980.tb01733.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Feely J., Wilkinson G. R., Wood A. J. Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med. 1981 Mar 19;304(12):692–695. doi: 10.1056/NEJM198103193041202. [DOI] [PubMed] [Google Scholar]
  13. Grainger S. L., Marigold J. H., Keeling P. W. Ranitidine and liver blood flow. Lancet. 1982 Feb 13;1(8268):398–398. doi: 10.1016/s0140-6736(82)91425-8. [DOI] [PubMed] [Google Scholar]
  14. Harris A., Cook P. J., Jewell D. P., James I. M. Cimetidine and cerebral blood flow in elderly patients. Br J Clin Pharmacol. 1981 Jan;11(1):93–94. doi: 10.1111/j.1365-2125.1981.tb01110.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Heagerty A. M., Donovan M. A., Castleden C. M., Pohl J. F., Patel L., Hedges A. Influence of cimetidine on pharmacokinetics of propranolol. Br Med J (Clin Res Ed) 1981 Jun 13;282(6280):1917–1919. doi: 10.1136/bmj.282.6280.1917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lebrec D., Nouel O., Bernuau J., Bouygues M., Rueff B., Benhamou J. P. Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients. Lancet. 1981 Apr 25;1(8226):920–921. doi: 10.1016/s0140-6736(81)91617-2. [DOI] [PubMed] [Google Scholar]
  17. Lebrec D., Nouel O., Corbic M., Benhamou J. P. Propranolol--a medical treatment for portal hypertension? Lancet. 1980 Jul 26;2(8187):180–182. doi: 10.1016/s0140-6736(80)90063-x. [DOI] [PubMed] [Google Scholar]
  18. Lee P. K., Lai C. L., Lok A. S., Tse T. F., Lai K. N., Chow S. F., Lam K. C. Haemodynamic responses to intravenous cimetidine in subjects with normal lung function and in subjects with chronic airway obstruction. Br J Clin Pharmacol. 1981 Apr;11(4):339–343. doi: 10.1111/j.1365-2125.1981.tb01130.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Neuvonen P. J., Tokola R. A., Kaste M. Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test. Eur J Clin Pharmacol. 1981;21(3):215–220. doi: 10.1007/BF00627923. [DOI] [PubMed] [Google Scholar]
  20. Ohnhaus E. E., Thorgeirsson S. S., Davies D. S., Breckenridge A. Changes in liver blood flow during enzyme induction. Biochem Pharmacol. 1971 Oct;20(10):2561–2570. doi: 10.1016/0006-2952(71)90164-x. [DOI] [PubMed] [Google Scholar]
  21. Richardson P. D., Withrington P. G. Liver blood flow. I. Intrinsic and nervous control of liver blood flow. Gastroenterology. 1981 Jul;81(1):159–173. [PubMed] [Google Scholar]
  22. Richardson P. D., Withrington P. G. Liver blood flow. II. Effects of drugs and hormones on liver blood flow. Gastroenterology. 1981 Aug;81(2):356–375. [PubMed] [Google Scholar]
  23. Richardson P. D., Withrington P. G. The vasodilator actions of isoprenaline, histamine, prostaglandin E2, glucagon and secretin on the hepatic arterial vascular bed of the dog. Br J Pharmacol. 1976 Aug;57(4):581–588. doi: 10.1111/j.1476-5381.1976.tb10388.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Roberts C. J., Jackson L., Halliwell M., Branch R. A. The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man. Br J Clin Pharmacol. 1976 Oct;3(5):907–913. doi: 10.1111/j.1365-2125.1976.tb00646.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Saltissi S., Crowther A., Byrne C., Coltart D. J. The effects of chronic oral cimetidine therapy on the cardiovascular system in man. Br J Clin Pharmacol. 1981 May;11(5):497–503. doi: 10.1111/j.1365-2125.1981.tb01156.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Schneider R. E., Bishop H. H2 receptor antagonists for portal hypertension. Lancet. 1981 Jul 18;2(8238):152–152. doi: 10.1016/s0140-6736(81)90333-0. [DOI] [PubMed] [Google Scholar]
  27. Serlin M. J., Sibeon R. G., Mossman S., Breckenridge A. M., Williams J. R., Atwood J. L., Willoughby J. M. Cimetidine: interaction with oral anticoagulants in man. Lancet. 1979 Aug 18;2(8138):317–319. doi: 10.1016/s0140-6736(79)90340-4. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES